Vivasure Medical Ltd. has designed a sutureless and absorbable venous vessel closure for use following percutaneous cardiovascular procedures, such as transcatheter mitral valve or tricuspid valve ...
Please provide your email address to receive an email when new articles are posted on . The CHOICE-CLOSURE trial was presented by Mohamed Abdel-Wahab, MD, consultant cardiologist and head of the ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that it will unveil the results of its U.S ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...
Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure ...
Approval brings proven technology of the MYNX family of products to mid-bore venous puncture sites, including electrophysiology procedures. MIAMI, July 9, 2024 /PRNewswire/ -- Cordis, a global leader ...
The AMBULATE Same-Day Discharge Clinical Study Series demonstrates safe and effective use of VASCADE MVP in three studies to date, with more than 800 AF ablation patients discharged the same calendar ...
12 month closure rates for the VenaSeal closure system comparable to radiofrequency ablation DUBLIN, Medtronic plc today announced the twelve-month results of the VeClose pivotal study, which ...
Vivasure Medical Ltd. has designed a sutureless and absorbable venous vessel closure for use following percutaneous cardiovascular procedures, such as transcatheter mitral valve or tricuspid valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results